StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABSW) stock analysis

SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30
$0.01+0.00 (+33.33%)

Close on Oct 20, 2026Market cap $304.80MP/E –Yield –

StockData Score

Prices as of Oct 30, 2026How the score works

Value1Growth0Performance1Health2Dividend0

Weak4 of 30 checks passed

SAB Biotherapeutics passes 4 of the 30 checks behind our score; 21 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
1/6
Growth
0/6
Past performance
1/6
Financial health
2/6
Dividend
0/6

What stands out

  • Low bankruptcy risk

    The Altman Z-score is 6.40; above 3 is the safe zone and below 1.8 the distress zone.

  • P/B below the industry

    SAB Biotherapeutics's price-to-book of 1.42 is below the Drugs median of 2.31.

  • Return on equity above the industry

    SAB Biotherapeutics's return on equity of -11.3% is above the Drugs median of -59.0%.

  • Short-term assets cover short-term debts

    Current assets are 9.22 times current liabilities.

What to watch

  • Return on equity under 15%

    Return on equity was -11.3% over the last twelve months and averaged -52.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -95.8%, below the 10% that usually covers the cost of capital.

  • Earnings shrank over 5 years

    Net income shrank 8.0% a year on average over the last five fiscal years.

  • Interest not well covered

    Operating income covers interest expense -310.3 times; we look for at least 5.

Valuation1/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B below the industry

    SAB Biotherapeutics's price-to-book of 1.42 is below the Drugs median of 2.31.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth0/6

  • Revenue growth over 3 years

    Needs three years of positive revenue.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growth against the industry

    Needs revenue for this year and last.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance1/6

  • Return on equity under 15%

    Return on equity was -11.3% over the last twelve months and averaged -52.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -95.8%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    SAB Biotherapeutics's return on equity of -11.3% is above the Drugs median of -59.0%.

  • Earnings shrank over 5 years

    Net income shrank 8.0% a year on average over the last five fiscal years.

  • Net margin against its history

    Needs five years of revenue and net income.

  • Net margin against the industry

    Needs revenue and net income.

Financial health2/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt coverage

    Needs operating cash flow.

  • Interest not well covered

    Operating income covers interest expense -310.3 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 9.22 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 6.40; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    SAB Biotherapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for SAB Biotherapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 1.3
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$2.14M
Value traded per 1% price move
$527.20K

Downside

Medium risk

Typical loss in a bad month
21.5%
Volatility (annualized)
61%
Sharpe ratio, 1 year
0.09
Beta to the S&P 500 (5Y)
1.41

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2019 to 2025

Operating margin

–

Net margin

–